Vanessa Pataia,  —

Adding Ensifentrine to Tiotropium Therapy Improves Lung Function in COPD, Top-line Results Show

Verona Pharma announced positive top-line results on the use of nebulized ensifentrine as an add-on to tiotropium (Spiriva Respimat) in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). The results come from a Phase 2b clinical trial (NCT03937479), which showed that ensifentrine — when…

New Combination Respiratory Therapy for COPD Approved by FDA

A new double-combination therapy that promotes lung expansion and airway clearance has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of people with lung diseases including chronic obstructive pulmonary disease (COPD) and asthma. The therapy was developed by the Monaghan Medical Corporation  and combines two…

COPD Triple-combination Therapy Approved in China, AstraZeneca Announces

AstraZeneca’s triple-combination therapy for people with chronic obstructive pulmonary disease (COPD) has been approved in China as a maintenance treatment. The therapy comprises three compounds: the corticosteroid budesonide, and two long-acting bronchodilators — glycopyrronium, a muscarinic antagonist, and formoterol fumarate, a β2-agonist. This combo…